CAPTRUST Financial Advisors
GALT icon

CAPTRUST Financial Advisors’s Galectin Therapeutics GALT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-213
Closed -$1K – 4675
2021
Q2 		$1K Buy
+213
New +$758 ﹤0.01% 4334

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

CAPTRUST Financial Advisors's GALT Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 213 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in GALT in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 213 Galectin Therapeutics shares in Q3 2021, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Galectin Therapeutics in Q2 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Galectin Therapeutics position peaked at $1K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.